Literature DB >> 29158163

Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas.

Melanie C Föll1, Matthias Fahrner2, Christine Gretzmeier3, Käthe Thoma3, Martin L Biniossek4, Dimitra Kiritsi3, Frank Meiss3, Oliver Schilling5, Alexander Nyström6, Johannes S Kern7.   

Abstract

In this study we used a genetic extracellular matrix (ECM) disease to identify mechanisms associated with aggressive behavior of cutaneous squamous cell carcinoma (cSCC). cSCC is one of the most common malignancies and usually has a good prognosis. However, some cSCCs recur or metastasize and cause significant morbidity and mortality. Known factors that are associated with aggressiveness of cSCCs include tumor grading, size, localization and microinvasive behavior. To investigate molecular mechanisms that influence biologic behavior we used global proteomic and histologic analyses of formalin-fixed paraffin-embedded tissue of primary human cSCCs. We compared three groups: non-recurring, non-metastasizing low-risk sporadic cSCCs; metastasizing sporadic cSCCs; and cSCCs from patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a genetic skin blistering and ECM disease caused by collagen VII deficiency. Patients commonly suffer from high-risk early onset cSCCs that frequently metastasize. The results indicate that different processes are associated with formation of RDEB cSCCs compared to sporadic cSCCs. Sporadic cSCCs show signs of UV damage, whereas RDEB cSCCs have higher mutational rates and display tissue damage, inflammation and subsequent remodeling of the dermal ECM as tumor initiating factors. Interestingly the two high-risk groups - high-risk metastasizing sporadic cSCCs and RDEB cSCCs - are both associated with tissue damage and ECM remodeling in gene-ontology enrichment and Search Tool for the Retrieval of Interacting Genes/Proteins analyses. In situ histologic analyses validate these results. The high-risk cSCCs also show signatures of enhanced bacterial challenge. Histologic analyses confirm correlation of bacterial colonization with worse prognosis. Collectively, this unbiased study - performed directly on human patient material - reveals that common microenvironmental alterations linked to ECM remodeling and increased bacterial challenges are denominators of high-risk cSCCs. The proteins identified here could serve as potential diagnostic markers and therapeutic targets in high-risk cSCCs.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Collagen VII; Dystrophic epidermolysis bullosa; FFPE proteomics; Invasion; Metastasis; Recurrence

Mesh:

Year:  2017        PMID: 29158163     DOI: 10.1016/j.matbio.2017.11.004

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  11 in total

1.  Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance.

Authors:  V O Oria; P Bronsert; A R Thomsen; M C Föll; C Zamboglou; Luciana Hannibal; S Behringer; M L Biniossek; C Schreiber; A L Grosu; L Bolm; D Rades; T Keck; M Werner; U F Wellner; O Schilling
Journal:  Transl Oncol       Date:  2018-08-30       Impact factor: 4.243

Review 2.  Recent advances in understanding and managing epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Alexander Nyström
Journal:  F1000Res       Date:  2018-07-17

Review 3.  Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.

Authors:  Angelo Giuseppe Condorelli; Elena Dellambra; Elena Logli; Giovanna Zambruno; Daniele Castiglia
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

4.  Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses.

Authors:  E Chacón-Solano; C León; F Díaz; F García-García; M García; M J Escámez; S Guerrero-Aspizua; C J Conti; Á Mencía; L Martínez-Santamaría; S Llames; M Pévida; J Carbonell-Caballero; J A Puig-Butillé; R Maseda; S Puig; R de Lucas; E Baselga; F Larcher; J Dopazo; M Del Río
Journal:  Br J Dermatol       Date:  2019-04-15       Impact factor: 9.302

Review 5.  Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Authors:  Verena Wally; Manuela Reisenberger; Sophie Kitzmüller; Martin Laimer
Journal:  Orphanet J Rare Dis       Date:  2020-10-19       Impact factor: 4.123

Review 6.  A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.

Authors:  Payal M Patel; Virginia A Jones; Christy T Behnam; Giovanni Di Zenzo; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2021-05-17

7.  Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.

Authors:  Susan J Robertson; Elizabeth Orrin; Manpreet K Lakhan; Gavin O'Sullivan; Jessie Felton; Alistair Robson; Danielle T Greenblatt; Catina Bernardis; John A McGrath; Anna E Martinez; Jemima E Mellerio
Journal:  Acta Derm Venereol       Date:  2021-08-24       Impact factor: 3.875

8.  Circular RNA profiles and the potential involvement of down-expression of hsa_circ_0001360 in cutaneous squamous cell carcinogenesis.

Authors:  Pingjiao Chen; Changxing Li; Hongchang Huang; Liuping Liang; Jing Zhang; Qian Li; Qi Wang; Sanquan Zhang; Kang Zeng; Xibao Zhang; Jingyao Liang
Journal:  FEBS Open Bio       Date:  2021-03-11       Impact factor: 2.693

9.  A Systematic Evaluation of Semispecific Peptide Search Parameter Enables Identification of Previously Undescribed N-Terminal Peptides and Conserved Proteolytic Processing in Cancer Cell Lines.

Authors:  Matthias Fahrner; Lucas Kook; Klemens Fröhlich; Martin L Biniossek; Oliver Schilling
Journal:  Proteomes       Date:  2021-05-25

10.  Translational perspectives to treat Epidermolysis bullosa-Where do we stand?

Authors:  Christine Prodinger; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2020-11       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.